María Isabel Martínez Rodríguez

Isabel Martínez Rodríguez Education 1992 Degree in Medicine and Surgery, University of Oviedo, Spain. 1998 Nuclear Medicine Specialist, Hospital Central de Asturias, Oviedo, Spain. 2001 PhD Thesis in Medicine, University of Oviedo, Spain. 2008 Certification of Special Competence in PET/CT, Barcelona, Spain. Career Profile Nuclear Medicine Physician at the Instituto Radiológico José Miranda, Oviedo, Spain from 2001 to 2004. Nuclear Medicine Physician at the Marqués de Valdecilla University Hospital of Santander, Spain, since 2005. Member of the Molecular Imaging Group of IDIVAL since 2014. President of the Committee of Tissues and Tumors and member of the Committee of Quality in Nuclear Medicine and the Central Committee of Quality of Care at the Marqués de Valdecilla University Hospital of Santander, Spain. Reviewer and member of the editorial committee of the journal "Revista Española de Medicina Nuclear e Imagen Molecular". Collaborator professor at the Department of Medical and Surgical Sciences of the University of Cantabria since 2016. Training of future Nuclear Medicine Specialists since 2005. Author or co-author of more than 70 peer-reviewed scientific articles with and H-Index of 7 (Web of Knowledge, accessed on September 14, 2017), and more than 150 contributions to scientific congresses, as well as several book chapters. Participation in 7 competitive research projects as principal investigator or collaborator. Award from Editorial Elsevier (2012) for Citations in scientific journals. Award from the British Nuclear Medicine Society at the 40th Annual Meeting (2012) for best poster, category of "Multimodality Poster Prize". Research interests: F-FDG PET/CT imaging in oncology. C-Choline PET/CT in prostate cancer. C-Methionine PET/CT in brain tumors, multiple myeloma and hyperparathyroidism. F-FDG and F-FNa PET/CT in inflammation (vasculitis, polymyalgia rheumatica, rheumatoid arthritis) and atheroma. Alpha-emitters radionuclide (Ra-223) for treatment of bone metastases in castration resistant prostate cancer. F-FDG PET/CT and C-PIB and I-123 Ioflupane in the study of biological bases of neurological diseases (Alzheimer's and Parkinson's diseases).